|1.||Jiang, Xiqun: 2 articles (10/2012 - 03/2009)|
|2.||Yu, Shuling: 1 article (10/2012)|
|3.||Cheng, Yuan: 1 article (10/2012)|
|4.||Qian, Hanqing: 1 article (10/2012)|
|5.||Wu, Wei: 1 article (10/2012)|
|6.||Wang, Jingjing: 1 article (10/2012)|
|7.||Li, Rutian: 1 article (03/2009)|
|8.||Li, Xiaolin: 1 article (03/2009)|
|9.||Liu, Baorui: 1 article (03/2009)|
|10.||Guo, Rui: 1 article (03/2009)|
10/01/2012 - "In vivo antitumor efficacy examinations indicate that DOX-loaded ALG-PDEA NPs have significantly superior efficacy in impeding tumor growth compared to free DOX and low toxicity to living mice."
10/01/2012 - "In vivo NIR fluorescence imaging shows that the ALG-PDEA NPs can passively target the tumor area because of the EPR effect in the H22 tumor-bearing mouse. "
03/01/2009 - "In vitro cell viability tests reveal that drug-loaded ALG-PDEA-Au hybrid nanospheres exhibit similar tumor cell inhibition to the free drug doxorubicin. "
03/01/2009 - "It is demonstrated that negatively charged ALG-PDEA-Au hybrid nanospheres can be internalized by human colorectal LoVo cancer cells and hence act as novel optical-contrast reagents in tumor-cell imaging by optical microscopy. "
|1.||Indicators and Reagents (Reagents)